LIFEVANTAGE CORP Effective Income Tax Rate Reconciliation Fdii Percent
LIFEVANTAGE CORP (LFVN) reported Effective Income Tax Rate Reconciliation Fdii Percent of 1.40% for the 12-month period ending 2025-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent · last filed 2026-08-27
- LIFEVANTAGE CORP effective income tax rate reconciliation fdii percent for fiscal 2025 was 1.40%, a 100.00% increase from fiscal 2024.
- LIFEVANTAGE CORP effective income tax rate reconciliation fdii percent for fiscal 2024 was 0.70%, a 87.93% decline from fiscal 2023.
- LIFEVANTAGE CORP effective income tax rate reconciliation fdii percent for fiscal 2023 was 5.80%, a 10.77% decline from fiscal 2022.
- LIFEVANTAGE CORP effective income tax rate reconciliation fdii percent for fiscal 2022 was 6.50%.
| Period end | Effective Income Tax Rate Reconciliation Fdii Percent 12 month |
|---|---|
| 2025-06-30 | 1.40% 10-K · filed 2026-08-27 |
| 2024-06-30 | 0.70% 10-K · filed 2025-09-04 |
| 2023-06-30 | 5.80% 10-K · filed 2024-08-28 |
| 2022-06-30 | 6.50% 10-K · filed 2023-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |